Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Meister Keith A. reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director Keith A. Meister received a stock award as part of his board compensation. He elected to take 100% of his 2026 board and committee cash retainer fees in Illumina stock, and for the second quarter 2026 this resulted in a grant of 142 shares at a reference price of $149.1868 per share. After this grant, he directly holds 6,780 shares of common stock, and additional Illumina securities are held indirectly for the accounts of private investment funds advised by Corvex Management LP, whose general partner is controlled by him.
Ullem Scott B. reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director Scott B. Ullem reported receiving 167 shares of common stock on June 30, 2026. The shares were valued at $149.1868 per share and were granted as compensation rather than purchased on the open market.
According to the footnote, Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. This particular grant represents his second quarter 2026 retainer fees and is based on the volume weighted average closing price during that quarter. Following this award, he directly holds 11,030 shares of Illumina common stock.
ILLUMINA, INC.'s Chief Legal Officer Scott M. Davies completed an open-market sale of company stock. He sold 615 shares of Common Stock at a price of $180 per share. After this transaction, he directly holds 20,953 Illumina shares, so the sale represents a small portion of his overall reported position.
Illumina affiliate submitted a Form 144 to sell shares. The filing lists proposed sales tied to Performance Stock Units and Restricted Stock Units with a reported 10b5-1 sale on 05/29/2026 for 98,400 common shares. The filing records an earlier grant date of 02/21/2023.
Frances Arnold reported proposed sales of Illumina common stock via a Form 144 notice. The filing lists multiple dispositions in May–June 2026, including sales of 3,000 shares on 06/02/2026 for $484,571.70 and 5,000 shares on 05/28/2026 for $780,650.00. The filing also records restricted stock vesting of 2,000 shares on 05/21/2026 under a registered compensation plan.
ILLUMINA, INC. director Daniel Skovronsky reported an acquisition of 1,674 shares of common stock through a grant of restricted stock units. These RSUs were valued at $164.28 per share for reporting purposes and represent his entire reported direct holding after the transaction.
According to the grant terms, 100% of the shares subject to this restricted stock unit award will vest on the earlier of the one-year anniversary of the grant date or the date immediately preceding the company’s next annual stockholder meeting for the following year, as long as he continues to serve as a director through that date.
ILLUMINA, INC. director Daniel Skovronsky filed an initial Form 3, which is a statement of beneficial ownership required when someone becomes an insider. The filing does not report any buy or sell transactions and serves mainly to put his insider status on record with regulators.
Illumina, Inc. increased its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D. as a director, effective June 16, 2026. He will stand for election at the company’s 2027 annual meeting of stockholders for a one-year term.
Dr. Skovronsky is deemed an independent director under applicable Nasdaq and SEC rules and will participate in Illumina’s non-employee director compensation programs. He currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, bringing deep experience in drug discovery, clinical development, and translational medicine relevant to Illumina’s genomics and multiomics platforms.
Illumina, Inc. senior vice president and Chief People Officer Patricia Leckman reported open-market sales of a total of 783 shares of common stock. The sales on June 5 occurred at prices ranging from $161.79 to $167.88 per share. After these transactions, she holds 21,259 shares directly.
Illumina filing a Form 144 notice for proposed resale of common shares. The excerpt lists broker/dealer UBS Financial Services, Nasdaq listing, and several security line items including PSU entries dated 02/21/2023 and 02/22/2022. The excerpt also shows a 06/05/2026 filing date and a selling holder identified as The Patricia L Leckman Trust dtd 5/21/2014.